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Abstract
The face of palliative care has changed considerably in the past four decades. The increased consump-
tion of opioids did not fulfil the promise of freedom from pain. The reason for this may be that cancer 
patients live longer and suffer from different types of pain than before. Increasingly, patients suffer because 
of treatment-induced pain and pain due to degeneration and deterioration. Different strategies for coping 
with pain are now needed in comparison with four decades ago.
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Introduction 
The credit for the development of palliative care 
and later palliative medicine should be given to Dame 
Cicely Saunders, who established the first modern 
hospice in South London in 1967 [1]. This institution 
and many that followed was meant to provide care 
for those with progressive and incurable diseases. The 
care was provided not only to the patients, but also to 
their families. Although the initial focus was on dying 
patients with cancer, palliative care evolved rapidly 
and hospices and palliative care units nowadays pro-
vide care whenever it is needed, independent of the 
type and advancement of diseases [1].
Important issues brought up by Dame Cicely and 
placed on the world agenda were the wider avail-
ability of opioids, especially morphine, and pain 
under-treatment. Morphine was coined as a gold 
standard and at that time it was believed that there 
was a linear relationship between the dose of mor-
phine and its analgesic effect. Not infrequently pa-
tients were treated with mega doses of opioids, 
something we do not now encounter every day [2]. 
In the focus on under-treatment, there was also a hid-
den promise: once we are able to treat everybody 
who needs it with morphine, the problem of pain, 
especially in cancer, can be solved.
Much has been done by Dame Cicely and her 
followers, among them Balfour Mount, Robert 
Twycross, Geoff Hanks, Vittorio Ventafridda and 
many others. The teaching of palliative care and 
pain treatment has become the norm in many uni-
versities. Much later than that, ongoing, extremely 
relevant research emerged on all continents. The 
numbers of hospices and palliative care units in-
creased to thousands and the specialty of Palliative 
Medicine emerged in several countries.
At that time, doctors were clearly recognizing 
that some pains would not respond to morphine 
or may respond initially but then become resistant 
to the drug at a later stage. It was thought that 
most of these aberrant pains were of neuropathic 
origin and that the addition of co-analgesics would 
solve the problem. In 1985 a simple scheme, the 
so-called WHO analgesic ladder, was launched [3]. 
This scheme was developed to fight cancer pain 
but became the standard in many other fields. 
The three steps, some of them still disputed [4, 5], 
Advances in Palliative Medicine 2011, vol. 10, no. 3–4
www.advpm.eu86
revolutionized the pain treatment in cancer. Good 
pain control became a human right and politicians, 
together with doctors and nurses, struggled side 
by side to achieve their goals: to build more hos-
pices, have them financed and break through the 
myths and prejudices about morphine and other 
opioids. Opioid consumption became a parameter 
of a country’s development in palliative care and 
a surrogate for its quality [6, 7].
The main idea of the WHO ladder was to “keep 
it simple”. However, the scheme simplified so much 
that the idea emerged that ALL pains in cancer could 
be treated with morphine ± co-analgesics [8, 9]. 
As a result of this, doctors did not bother to investi-
gate and describe pain well because the treatment 
was always the same. 
In this article we shall reflect on what happened 
next and where we are now concerning pain in 
cancer. We may also look a little way into the future.
Do cancer patients live longer?
In the past 40 years we have been through a true 
revolution in oncology. Although the numbers of 
patients cured from cancer have increased slowly 
but steadily, the kinds of cancer that can be cured 
have not changed much [10, 11]. However, the pa-
tients with the most common cancers do live longer 
and in many cases cancer became a chronic disease 
with survival rates superior to those of chronic kidney 
or liver diseases [11].
Does living longer means suffering 
longer pain?
In a recent meta-analysis of 154 trials it 
was found that approximately half the patients with 
cancer of all stages suffer from pain [12].When the 
cancer is more advanced, the numbers are approxi-
mately 10% higher. New in this analysis was that 
approximately one third of patients under active 
treatment suffer from pain and also that there 
is a large group (33%) of cancer survivors who 
suffer from pain [12].
What does this mean? First of all, it means that 
the numbers of patients with advanced cancer and 
pain have not changed in the past 40 years. Modern 
oncology prolongs patients’ survival, but does not 
cure the pain; at least, not for ever and not when the 
tumour has become far advanced. The patients after 
treatment may enjoy longer periods without pain 
but may also suffer longer periods with discomfort 
and pain later.
Pain treatment in a patient 
with a short prognosis is easier
Forty years ago, the time of great enthusiasm 
around opioid use, patients were treated with 
opioids for shorter periods of time simply because 
they were dying much earlier. Phenomena such 
as opioid tolerance, drug addiction and loss of 
analgesic potential were seldom observed. They 
were also, for political reasons, found to be unim-
portant and insignificant. We needed to convince 
prescribers not to be afraid of these phenomena. 
On the other hand, some types of pain, especially 
neuropathic pain were also seen less often. After 
damage to the nerve, it takes a couple of months to 
develop a full picture of neuropathic pain [13, 14]. 
It is thus conceivable that 40 years ago we en-
countered neuropathic pain less often as patients’ 
survival was much shorter. However, this is not yet 
confirmed by epidemiologists.
What do cancer survivors tell us?
A new group, which remained unseen for a long 
time, was that of the cancer survivors. This group 
is becoming larger and larger. In one third of them, 
any good effect of treatment was exchanged for 
pain as a result of healthy tissue damage due to ag-
gressive treatment [12]. Modern oncology treatment 
may irreversibly damage skin, nerves, bones and 
other tissues. The pains emerging from the treat-
ment cannot be classified as “cancer pain” (as the 
cancer is gone) and will frequently not respond to 
opioids. It is conceivable, but still not documented 
by epidemiologists, that patients who are not cured 
from cancer are, besides the damage due to the 
tumour growth, also suffering the same damage to 
tissues due to the treatment. 
“Cancer pain” or “pain in cancer”?
Taking these data altogether, one could think that 
the qualities of pain encountered in patients with can-
cer nowadays may be different from forty years ago. 
The percentage of patients suffering opioid-resistant 
pains could be higher than previously. It is thus better 
not to call all pains “cancer pains” but to differenti-
ate them for each patient and treat them separately. 
It would also be well to remember that the simple 
World Health Organization (WHO) analgesic ladder 
was mainly designed for generic “cancer pain” and 
most of the “cancer pain” was considered sensitive 
to opioids.
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Opioid consumption
As a consequence of the efforts of pioneers, 
opioid consumption rose dramatically over the past 
40 years [15, 16]. Sometimes tenfold or more. While 
there are still many countries which are underusing 
opioids, frequently for cultural reasons, we are now 
in the rich West confronted with countries whose 
populations consume very high amounts of opio-
ids. In these countries, it is not under-treatment 
but over-treatment and opioid toxicity which have 
become a problem.
Progress in pain control?
In fact, most progress in pain control has been 
made in the area of “true cancer pain”, which 
means pains directly related to tumour growth 
(compression or infiltration by tumour). The most 
successful technologies in treating this kind of pain 
have been radio-, hormone- and chemotherapy. 
Opioids are only adjunctive to these techniques and 
cannot deal with the pain alone. By treating the 
tumours aggressively we decrease the likelihood of 
tumour-related pain but increase the likelihood of 
pain due to tissue damage and degeneration. These 
latter are less prone to responding to opioids.
Thus, in thinking of “cancer pain” which 
needs opioids and is usually “opioid sensitive”, we 
may overdose some patients and treat them with 
toxic doses. These patients may also be so kind 
to us as to die earlier due to opioids before larger 
problems appear.
New phenomena related to opioid 
toxicity
Cognitive impairment
New phenomena, previously unknown or not 
considered important, have emerged in the last 
decade. The first of these is cognitive failure. Opio-
ids, while effective against many pains, may also 
induce progressive cognitive impairment [17–19]. 
Occasionally, this may progress to delirium and psy-
chosis. For a long time it was thought fair to control 
somebody’s pain at the cost of (slight) cognitive 
impairment. However, when treatment with opio-
ids needed to be extensive, cognitive impairment 
became a problem, compromising patients’ quality 
of life. New technologies, sometimes invasive and 
risky, emerged for treating pain without or with 
lower doses of opioids. These techniques were, 
however, discouraged because of their invasive-
ness and difficulty in accessing them but mainly 
because of the risk of pain exacerbation instead of 
its annihilation. At the moment cognitive impairment 
is seen as a symptom of neurotoxicity and several 
approaches to it have been developed. 
Opioid-induced hyperalgesia (OIH)
When opioids are administered for a longer time, 
patients may notice that their analgesic potency 
decreases and also that the quality of pain changes. 
This phenomenon may be more common than previ-
ously thought [20]. From the focal pain due to cancer 
growth clearly seen on the MRI, patients start to 
suffer from more generalized pain which is unex-
plainable with the advent of modern diagnostic tech-
niques. It is highly probable that some patients are 
particularly sensitive to these phenomena, which in 
general depend on pain facilitation in the spinal cord 
[21, 22]. In these patients OIH may emerge rapidly 
within hours or days after commencement of treat-
ment. However, most vulnerable is the population 
of (former) drug addicts, who frequently develop 
OIH and may suffer severe pain when later having 
cancer.Different opioids may influence OIH in a dif-
ferent manner. Some opioids are potent OIH induc-
ers, others not. Thus, opioid switching can help for 
a while [23].
Opioid-induced hypogonadism
Another phenomenon, known about for more 
than 100 years, is opioid-induced hypogonadism 
[24]. Morphine and most other opioids (except 
buprenorphine) [25–27] inhibit the hypophyseal 
excretion of gonadotropic hormones. When the 
gonads and adrenals are not stimulated by gona-
dotropins, they do not produce sex hormones and 
we are then talking about hypogonadism. The main 
issue in hypogonadism is that the patients feel fa-
tigued, have increased sensitivity to pain, but also 
suffer from a number of degenerative disorders, 
such as osteoporosis and muscle and skin atrophy, 
all of which can be the source of new pain [28–31]. 
Hypogonadism may also be correlated with adrenal 
insufficiency and may exacerbate it. It has been 
estimated that over 80% of patients treated with 
opioids for a long time suffer because of hypogo-
nadism [24]. Yet, this phenomenon was neglected in 
research for a long time. Again, patients lived too 
short a time to be bothered by this phenomenon. 
Hormone substitution, although cheap and possible, 
has not attracted much attention and we are left with 
a small number of case reports and anecdotes but 
no trials or evidence.
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Conclusion
The patient who is seeking our advice in the year 
2011 is a different patient from four decades ago. 
Potentially, he will suffer from different kinds of 
pain and will show different sensitivity to opioids. 
He may have a chance of being treated with high 
doses of opioids and may suffer from the long-term 
adverse effects of opioids, which are still poorly re-
searched and do not attract much attention from the 
oncology community. Oncology has taken a major 
step forward but has left palliative care somewhat 
behind. Palliative care should recognize this and 
stop chasing ideals dating from four decades ago, 
and instead formulate new targets and develop new 
treatments. Recognizing each pain separately and 
finding the appropriate treatment for each of them 
is the key to success. Be careful, however. If we do 
not keep it simple, as advised before, we may end 
up in a complicated mess and make more (some-
times fatal) mistakes than before.
The key advice for the doctors and nurses involved 
in the care of patients with cancer is that there is no 
“cancer pain”; only “pain in cancer”.
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